🚀 VC round data is live in beta, check it out!
Prenetics Global Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prenetics Global and similar public comparables like SOPHiA Genetics, ToolGen, Atrys Health, Cibus and more.
Prenetics Global Overview
About Prenetics Global
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world’s fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Founded
2014
HQ
Employees
285
Website
Sectors
Financials (LTM)
EV
$263M
Prenetics Global Financials
Prenetics Global reported last 12-month revenue of $119M and negative EBITDA of ($14M).
In the same LTM period, Prenetics Global generated $67M in gross profit, ($14M) in EBITDA losses, and had net loss of ($56M).
Revenue (LTM)
Prenetics Global P&L
In the most recent fiscal year, Prenetics Global reported revenue of $31M and EBITDA of ($52M).
Prenetics Global expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $119M | XXX | $31M | XXX | XXX | XXX |
| Gross Profit | $67M | XXX | $15M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | ($14M) | XXX | ($52M) | XXX | XXX | XXX |
| EBITDA Margin | (12%) | XXX | (168%) | XXX | XXX | XXX |
| EBIT Margin | (34%) | XXX | (166%) | XXX | XXX | XXX |
| Net Profit | ($56M) | XXX | ($46M) | XXX | XXX | XXX |
| Net Margin | (47%) | XXX | (151%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Prenetics Global Stock Performance
Prenetics Global has current market cap of $285M, and enterprise value of $263M.
Market Cap Evolution
Prenetics Global's stock price is $16.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $263M | $285M | 0.0% | XXX | XXX | XXX | $-2.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrenetics Global Valuation Multiples
Prenetics Global trades at 2.2x EV/Revenue multiple, and (18.4x) EV/EBITDA.
EV / Revenue (LTM)
Prenetics Global Financial Valuation Multiples
As of April 8, 2026, Prenetics Global has market cap of $285M and EV of $263M.
Equity research analysts estimate Prenetics Global's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prenetics Global has a P/E ratio of (5.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $285M | XXX | $285M | XXX | XXX | XXX |
| EV (current) | $263M | XXX | $263M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | (18.4x) | XXX | (5.1x) | XXX | XXX | XXX |
| EV/EBIT | (6.5x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | 17.1x | XXX | XXX | XXX |
| P/E | (5.1x) | XXX | (6.2x) | XXX | XXX | XXX |
| EV/FCF | (11.5x) | XXX | (8.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prenetics Global Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Prenetics Global Margins & Growth Rates
Prenetics Global's revenue in the last 12 month grew by 88%.
Prenetics Global's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Prenetics Global's rule of 40 is 99% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prenetics Global's rule of X is 262% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Prenetics Global Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 88% | XXX | 202% | XXX | XXX | XXX |
| EBITDA Margin | (12%) | XXX | (168%) | XXX | XXX | XXX |
| EBITDA Growth | (33%) | XXX | (75%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 99% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 262% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 41% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 41% | XXX | 153% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 216% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Prenetics Global Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SOPHiA Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Atrys Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Cibus | XXX | XXX | XXX | XXX | XXX | XXX |
| Atlantic International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prenetics Global M&A Activity
Prenetics Global acquired XXX companies to date.
Last acquisition by Prenetics Global was on XXXXXXXX, XXXXX. Prenetics Global acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Prenetics Global
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPrenetics Global Investment Activity
Prenetics Global invested in XXX companies to date.
Prenetics Global made its latest investment on XXXXXXXX, XXXXX. Prenetics Global invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Prenetics Global
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prenetics Global
| When was Prenetics Global founded? | Prenetics Global was founded in 2014. |
| Where is Prenetics Global headquartered? | Prenetics Global is headquartered in Hong Kong. |
| How many employees does Prenetics Global have? | As of today, Prenetics Global has over 285 employees. |
| Who is the CEO of Prenetics Global? | Prenetics Global's CEO is Sheng Wu Danny Yeung. |
| Is Prenetics Global publicly listed? | Yes, Prenetics Global is a public company listed on Nasdaq. |
| What is the stock symbol of Prenetics Global? | Prenetics Global trades under PRE ticker. |
| When did Prenetics Global go public? | Prenetics Global went public in 2022. |
| Who are competitors of Prenetics Global? | Prenetics Global main competitors are SOPHiA Genetics, ToolGen, Atrys Health, Cibus. |
| What is the current market cap of Prenetics Global? | Prenetics Global's current market cap is $285M. |
| What is the current revenue of Prenetics Global? | Prenetics Global's last 12 months revenue is $119M. |
| What is the current revenue growth of Prenetics Global? | Prenetics Global revenue growth (NTM/LTM) is 88%. |
| What is the current EV/Revenue multiple of Prenetics Global? | Current revenue multiple of Prenetics Global is 2.2x. |
| Is Prenetics Global profitable? | No, Prenetics Global is not profitable. |
| What is the current EBITDA of Prenetics Global? | Prenetics Global has negative EBITDA and is not profitable. |
| What is Prenetics Global's EBITDA margin? | Prenetics Global's last 12 months EBITDA margin is (12%). |
| What is the current EV/EBITDA multiple of Prenetics Global? | Current EBITDA multiple of Prenetics Global is (18.4x). |
| What is the current FCF of Prenetics Global? | Prenetics Global's last 12 months FCF is ($23M). |
| What is Prenetics Global's FCF margin? | Prenetics Global's last 12 months FCF margin is (19%). |
| What is the current EV/FCF multiple of Prenetics Global? | Current FCF multiple of Prenetics Global is (11.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.